SLP Simulations Plus

Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference

LANCASTER, Calif.--(BUSINESS WIRE)--

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on Thursday, May 20, 2021, at 1:30 p.m. ET. In addition to his presentation, Mr. O’Connor will be joined by chief financial officer Will Frederick to host one-on-one meetings throughout the day.

This year’s conference will provide shareholders and investors the opportunity to see presentations from more than 350 public and private company management teams. For more information about the conference or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at , or visit the .

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at . Follow us on | Read our .

EN
13/05/2021

Underlying

SLPSimulations Plus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Simulations Plus

 PRESS RELEASE
Free
SLP Simulations Plu...

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that the U.S. FDA has renewed its licenses to the software platform. DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI). The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions. DILIsym predict...

April 4, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18.3 million Software revenue increased 11% to $11.6 million, representing 63% of total revenue Services revenue increased 27% to $6.7 million, representing 37% of total revenue Gro...

April 3, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings an...

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this link t...

March 20, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Lif...

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time. In addition, Mr. O’Connor will be meeting one-on-one with investors throughout the day. The live webcast of the Company’s presentation can be accessed via this and ...

March 13, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus and the University of Bath Awarded New FDA Grant

LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with the University of Bath’s Department of Life Sciences and other university partners, it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA). The grant will be used to expand and validate a multi-functional, multi-purpose physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling solution for topical product...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch